Retatrutide, by Soma Pharmaceuticals , is receiving increasing attention as a innovative treatment for metabolic management . This dual-action compound integrates the properties of a GLP-1 receptor stimulant and a GIP receptor agonist , intended to effectively promote weight loss but also improve underlying metabolic factors. Early clinical studies